---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-124546"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:54:28.008970+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome Q3 revenue $104.8M (+81% YoY); Auvelity $80.4M (+113%); net loss $64.6M

## Summary
- Total net product revenue $104.8M, up 81% YoY; Auvelity $80.4M (+113%), Sunosi $24.4M (+21%).
- Net loss $64.6M ($1.34 loss per share); cash and equivalents $327.3M at Sept 30, 2024.
- Auvelity sales force to expand to ~300 reps in Q1 2025 due to strong demand growth.
- AXS-07 migraine NDA resubmission accepted with PDUFA goal date January 31, 2025.
- Topline results for AXS-05 (AD agitation) and AXS-12 (narcolepsy) on track for Q4 2024.

## SEC filing metadata
- accession: 0000950170-24-124546
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/0000950170-24-124546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024124546/axsm-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-124546
- JSON: https://secwatch.observer/filing/0000950170-24-124546.json
- Plain text: https://secwatch.observer/filing/0000950170-24-124546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.